Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer

NCT00673504 is registered in ClinicalTrials.gov with Central European Society for Anticancer Drug Research as lead sponsor.

NCT NCT00673504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00673504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer
Lead sponsor
Central European Society for Anticancer Drug Research
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
November 30, 2011
Enrollment
105 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer